NTLA - Biotech And Pharma Diversification Pays Off

2024-01-25 08:00:00 ET

Summary

• Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors.
• Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected.
• Competitive stories in gene editing therapy, Type 2 diabetes and obesity.
• Getting realistic about high price of drugs.

Listen below or on the go via Apple Podcasts or Spotify .

Alex Carchidi dissects the biotech sector - mostly highly risky, borderline investments. Diversification pays off (3:40). Funding is hard to come by and performance hasn't been great but ebb will give way to flow (6:00). Gene editing therapy competitive story (7:45). Buy the rumor, sell the news is cliched but true for these stocks (17:00). Getting realistic about high price of drugs (20:05).

Transcript

Rena Sherbill: Alex Carchidi, welcome back to Investing Experts. Welcome back to Seeking Alpha. Always great talking to you. So, thanks for making the time again.

Alex Carchidi: Thank you. I'm excited to be back. We have so many great conversations that I'm eager to dive in.

RS : Likewise, likewise. For those who know you from covering the psychedelic and also at times the cannabis space, you've been on The Cannabis Investing Podcast a few times talking the psychedelics sector and it's always brought a lot of edification and information. And through those conversations, I've gleaned your biotech background and your coverage of that sector and your interest in that sector.

So I thought, what better place to have you back on the show than Investing Experts talking biotech. So, if you would share with listeners your background in the biotech field and what brings you to cover that part of the marketplace?

AC : Definitely. So, first thing out of college, I started to work in an academic research laboratory doing vaccine research to make an HIV vaccine. It's the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard. Wonderful institution. They do a lot of wonderful research. I got my career started there. Then I worked at a couple of biotech startups in the Boston area, which is where I live, which is where there's tremendous number of different biotech and pharma companies....

For further details see: